Amgen(US:AMGN) Yahoo Finance·2025-12-03 06:57Core Viewpoint - Amgen Inc. is recognized as one of the Best Low Volatility Investments for December 2025, with Goldman Sachs maintaining a $400 price target and a Buy rating ahead of important updates on its obesity medication, MariTide [1]. Group 1: Investment Potential - Goldman Sachs anticipates long-term weight loss results with reduced or occasional dosage and minimal gastrointestinal side effects from the obesity maintenance data [2]. - The Phase 2 study of MariTide demonstrated an average weight loss of up to 20% in patients with obesity without Type 2 diabetes (T2D) and approximately 17% in those with T2D, alongside improvements in cardiometabolic parameters such as waist circumference and blood pressure [3]. Group 2: Company Overview - Amgen Inc. is involved in the discovery, development, manufacturing, and delivery of human therapeutics globally, serving healthcare providers including physicians, dialysis centers, hospitals, and pharmacies [4].